MMC Laboratories operates in full compliance with EU Good Manufacturing Practice (EU GMP) as defined by the European Commission in EudraLex Volume 4, ensuring that all activities, from cultivation support to distribution, are controlled, documented, and inspection-ready. The company maintains strong governance, data integrity (ALCOA+), and regulatory engagement to ensure transparency, traceability, and adherence to all applicable requirements.

MMC Laboratories is committed to consistently delivering safe, effective, and high-quality medical cannabis products. This is achieved through robust process controls, validated systems, qualified suppliers, and comprehensive Quality Control testing, ensuring that all products meet predefined specifications throughout their lifecycle.

MMC operates a fully integrated Pharmaceutical Quality System aligned with ICH Q10, covering all GMP-relevant activities including manufacturing, quality control, storage, distribution, validation, change control, deviations, CAPA, and complaints. Risk-based decision-making is applied in accordance with ICH Q9 to ensure scientific and proportionate control of quality risks.

MMC Laboratories drives continual improvement through ongoing monitoring of quality performance indicators, internal audits, self-inspections, and Product Quality Reviews. Lessons learned from deviations, complaints, and regulatory inspections are systematically implemented to strengthen the effectiveness of the Pharmaceutical Quality System.

MMC ensures that all personnel are appropriately qualified, trained, and competent to perform their roles. Continuous training programs, including GMP, job specifics, and data integrity, are implemented and regularly assessed for effectiveness, supporting a strong quality culture and consistent operational excellence.